Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases

Leeman, JE and Clump, DA and Wegner, RE and Heron, DE and Burton, SA and Mintz, AH (2012) Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases. Radiation Oncology, 7 (1).

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (355kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Background: Brainstem metastases represent an uncommon clinical presentation that is associated with a poor prognosis. Treatment options are limited given the unacceptable risks associated with surgical resection in this location. However, without local control, symptoms including progressive cranial nerve dysfunction are frequently observed. The objective of this study was to determine the outcomes associated with linear accelerator-based stereotactic radiotherapy or radiosurgery (SRT/SRS) of brainstem metastases.Methods: We retrospectively reviewed 38 tumors in 36 patients treated with SRT/SRS between February 2003 and December 2011. Treatment was delivered with the Cyberknife™ or Trilogy™ radiosurgical systems. The median age of patients was 62 (range: 28-89). Primary pathologies included 14 lung, 7 breast, 4 colon and 11 others. Sixteen patients (44%) had received whole brain radiation therapy (WBRT) prior to SRT/SRS; ten had received prior SRT/SRS at a different site (28%). The median tumor volume was 0.94 cm3 (range: 0.01-4.2) with a median prescription dose of 17 Gy (range: 12-24) delivered in 1-5 fractions.Results: Median follow-up for the cohort was 3.2 months (range: 0.4-20.6). Nineteen patients (52%) had an MRI follow-up available for review. Of these, one patient experienced local failure corresponding to an actuarial 6-month local control of 93%. Fifteen of the patients with available follow-up imaging (79%) experienced intracranial failure outside of the treatment volume. The median time to distant intracranial failure was 2.1 months. Six of the 15 patients with distant intracranial failure (40%) had received previous WBRT. The actuarial overall survival rates at 6- and 12-months were 27% and 8%, respectively. Predictors of survival included Graded Prognostic Assessment (GPA) score, greater number of treatment fractions, and higher prescription dose. Three patients experienced acute treatment-related toxicity consisting of nausea (n = 1) and headaches (n = 2) that resolved with a short-course of dexamethasone.Conclusion: SRT/SRS for brainstem metastases is safe and achieves a high rate of local control. We found higher GPA as well as greater number of treatment fractions and higher prescription dose to be correlated with improved overall survival. Despite this approach, prognosis remains poor and distant intracranial control remains an issue, even in patients previously treated with WBRT. © 2012 Leeman et al.; licensee BioMed Central Ltd.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Leeman, JE
Clump, DAdac158@pitt.eduDAC158
Wegner, RE
Heron, DEdeh5@pitt.eduDEH5
Burton, SA
Mintz, AH
Centers: Other Centers, Institutes, or Units > Pittsburgh Cancer Institute
Date: 11 July 2012
Date Type: Publication
Journal or Publication Title: Radiation Oncology
Volume: 7
Number: 1
DOI or Unique Handle: 10.1186/1748-717x-7-107
Schools and Programs: School of Medicine > Neurological Surgery
School of Medicine > Otolaryngology
School of Medicine > Radiation Oncology
School of Medicine > Surgery
Refereed: Yes
Date Deposited: 29 Nov 2016 21:03
Last Modified: 16 Feb 2019 23:55
URI: http://d-scholarship.pitt.edu/id/eprint/29866

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item